
Acumen Pharmaceuticals, Inc.: updates and filings
Price
$0.19
November 20, 2026Market cap $13M
What Ploutos Investor adds for Acumen Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 92% since Oct 26, 2026, when the 10-Q these figures come from was filed ($2.27 then, $0.19 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
October 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 5, 2026Material agreement ended, restructuring costsForm8-K
- Oct 30, 2026Regulation FD disclosure, other material eventsForm8-K
- Oct 28, 2026FilingFormEFFECT
- Oct 26, 2026Shelf registration for future offeringsFormS-3
- Oct 26, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 26, 2026Results of operations, Regulation FD disclosureForm8-K
- Sep 16, 2026Regulation FD disclosureForm8-K
- Aug 12, 2026FilingFormDRS
- Aug 12, 2026Shares registered for employeesFormS-8
- Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Jun 16, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 3, 2026Shareholder voteForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Apr 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 1, 2026FilingFormEFFECT
- Mar 30, 2026Correspondence with the SECFormCORRESP
- Mar 30, 2026Letter from the SECFormUPLOAD
- Mar 26, 2026Shelf registration for future offeringsFormS-3
- Mar 26, 2026Shares registered for employeesFormS-8
- Mar 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 5, 2026 | 8-K | Material agreement ended, restructuring costs | Document |
| Oct 30, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Oct 28, 2026 | EFFECT | Filing | Document |
| Oct 26, 2026 | S-3 | Shelf registration for future offerings | Document |
| Oct 26, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 26, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Sep 16, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 12, 2026 | DRS | Filing | Document |
| Aug 12, 2026 | S-8 | Shares registered for employees | Document |
| Aug 12, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jun 16, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 3, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 1, 2026 | EFFECT | Filing | Document |
| Mar 30, 2026 | CORRESP | Correspondence with the SEC | Document |
| Mar 30, 2026 | UPLOAD | Letter from the SEC | Document |
| Mar 26, 2026 | S-3 | Shelf registration for future offerings | Document |
| Mar 26, 2026 | S-8 | Shares registered for employees | Document |
| Mar 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since May 15, 2013.
The full analysis
What do Acumen Pharmaceuticals's filings show?
The filings are where every one of Acumen Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.